BACKGROUND: To evaluate the effect of paclitaxel/cisplatin induction chemotherapy (ICHT) and CT-based radiotherapy (RT) on larynx preservation, tumor control, and survival in patients with larynx/hypopharynx carcinoma eligible for total laryngectomy (TL) or TL plus partial pharyngectomy (TLPP). PATIENTS AND METHODS: Fifty patients eligible for TL or TLPP were enrolled onto a prospective study and treated with ICHT (200 mg/m(2) paclitaxel, 100 mg/m(2) cisplatin; day 1, 22). In patients with complete or partial tumor response RT (69.9 Gy in 5.5 weeks at the gross tumor, 50.4 Gy in the lymphatic drainage; single dose: 1.8 Gy, concomitant boost: 1.5 Gy) was applied. Non-responders had TL/TLPP and RT with total doses adapted to the radicality of tumor resection (56-70 Gy). RESULTS: The response rate to ICHT was 88% (10% complete, 78% partial response). At a median follow-up period of 25 months the larynx preservation rate was 84%. The 2-year local-regional control rate was 91% and the 2-year overall survival rate was 72.3%. The 3-year estimate to survive with functional larynx is 60%. CONCLUSION: In a large portion of patients eligible for TL or TLPP the larynx was preserved by paclitaxel/cisplatin ICHT and 3D RT.
BACKGROUND: To evaluate the effect of paclitaxel/cisplatin induction chemotherapy (ICHT) and CT-based radiotherapy (RT) on larynx preservation, tumor control, and survival in patients with larynx/hypopharynx carcinoma eligible for total laryngectomy (TL) or TL plus partial pharyngectomy (TLPP). PATIENTS AND METHODS: Fifty patients eligible for TL or TLPP were enrolled onto a prospective study and treated with ICHT (200 mg/m(2) paclitaxel, 100 mg/m(2) cisplatin; day 1, 22). In patients with complete or partial tumor response RT (69.9 Gy in 5.5 weeks at the gross tumor, 50.4 Gy in the lymphatic drainage; single dose: 1.8 Gy, concomitant boost: 1.5 Gy) was applied. Non-responders had TL/TLPP and RT with total doses adapted to the radicality of tumor resection (56-70 Gy). RESULTS: The response rate to ICHT was 88% (10% complete, 78% partial response). At a median follow-up period of 25 months the larynx preservation rate was 84%. The 2-year local-regional control rate was 91% and the 2-year overall survival rate was 72.3%. The 3-year estimate to survive with functional larynx is 60%. CONCLUSION: In a large portion of patients eligible for TL or TLPP the larynx was preserved by paclitaxel/cisplatin ICHT and 3D RT.
Authors: Andreas Dietz; Andreas Boehm; Iris-Susanne Horn; Pierre Kruber; Ingo Bechmann; Wojciech Golusinski; Dietger Niederwieser; Ralph Dollner; Torsten W Remmerbach; Christian Wittekind; Stephan Dietzsch; Guido Hildebrandt; Gunnar Wichmann Journal: Eur Arch Otorhinolaryngol Date: 2010-01-06 Impact factor: 2.503
Authors: Andreas Dietz; Volker Rudat; Jens Dreyhaupt; Maria Pritsch; Florian Hoppe; Rudolph Hagen; Leo Pfreundner; Ursula Schröder; Hans Eckel; Markus Hess; Michael Schröder; Petra Schneider; Bünzel Jens; Hans P Zenner; Jochen A Werner; Rita Engenhardt-Cabillic; Bernhard Vanselow; Peter Plinkert; Marcus Niewald; Thomas Kuhnt; Wilfried Budach; Michael Flentje Journal: Eur Arch Otorhinolaryngol Date: 2008-10-30 Impact factor: 2.503
Authors: Krzysztof Małecki; Bogdan Gliński; Anna Mucha-Małecka; Janusz Ryś; Anna Kruczak; Krzysztof Roszkowski; Marta Urbańska-Gąsiorowska; Marcin Hetnał Journal: Rep Pract Oncol Radiother Date: 2010-08-03
Authors: Thomas Kuhnt; Axel Becker; Marc Bloching; Johannes Schubert; Gunther Klautke; Rainer Fietkau; Juergen Dunst Journal: Med Oncol Date: 2006 Impact factor: 3.738